← All trials
NCT06256484
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2024
- Primary completion
- May 31, 2026
- Completion date
- Nov 30, 2028
- First posted
- Feb 13, 2024
- Last posted
- Aug 26, 2024
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Atara BiotherapeuticsLead sponsor
- Atara BiotherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.